论文部分内容阅读
目的:观察血塞通用于脑梗死患者治疗的临床疗效。方法:取本院2008年3月～2011年3月间收治的脑梗死患者124人,随机分为观察组和对照组,对照组给予常栓治疗,静脉推注重组织型纤溶酶原激活剂45mg;观察组在常规常栓治疗的基础上加用血塞通180mg静滴,1次/d,15天一疗程。根据2组病情适时进行降颅内压、调节血压血糖等对症治疗。观察2组功能疗效评级及血管再通率。结果:对脑梗死患者进行24小时治疗后,观察组总有效率(痊愈+显效+有效)为87.1%;对照组总有效率为51.6%,两者比较有统计学差异,P<0.05;观察组治疗后血管再通16例,占25.8%,对照组血管再通6例,占9.7%,两者比较有统计学差异,P<0.05。结论:血塞通是一种切实有效的用于脑梗死患者的治疗药物,值得在临床中广泛推广应用。
Objective: To observe the clinical efficacy of Xuesaitong in patients with cerebral infarction. Methods: A total of 124 patients with cerebral infarction who were treated in our hospital from March 2008 to March 2011 were randomly divided into observation group and control group. The control group was treated with continuous suppository, and intravenous infusion of recombinant tissue plasminogen activator 45mg; observation group in the conventional treatment of regular plug plus Xuesaitong 180mg intravenous infusion, 1 / d, 15 days a course of treatment. According to the two groups of patients in time to reduce intracranial pressure, blood pressure and other symptomatic treatment. The functional curative effect and revascularization rate of the two groups were observed. Results: After 24 hours treatment, the total effective rate (recovery + effective + effective) in the observation group was 87.1%; the total effective rate in the control group was 51.6%, the difference between the two groups was statistically significant (P <0.05) There were 16 cases of recanalization after treatment (25.8%) and 6 cases of recanalization in control group (9.7%), the difference was statistically significant (P <0.05). Conclusion: Xuesaitong is an effective and effective therapeutic drug for patients with cerebral infarction, which is worth widely used in clinical practice.